Appealing an NCPDP 75 Prior-Authorization Reject: What Actually Works in 2026

You're in the middle of a busy day, a patient is waiting at the pharmacy counter, and the claim just came back with a reject 75. For anyone who's worked in pharmacy billing or prior authorization long enough, that two-digit code carries a familiar sting. Reject 75 — "Prior Authorization Required" — is one of the most common NCPDP transaction rejects out there, and yet it still trips up practices and pharmacies that haven't built a clean process around it. The good news? A well-executed appeal can absolutely overturn these denials, often faster than people expect. Here's what you need to know to fight them effectively in 2026.

---

What Reject 75 Actually Means (And Why It Happens More Than It Should)

Let's start with the basics, because the details matter here. When a pharmacy submits a claim through the NCPDP standard transaction set and gets back reject 75, the PBM is saying that the drug requires prior authorization — and either no PA is on file, or the one that exists doesn't match the claim being submitted.

That sounds simple, but the reasons behind a 75 reject are surprisingly varied:

• No PA was ever submitted — the prescriber or their staff didn't know it was required


• PA was approved but linked to the wrong NPI, drug strength, or quantity


• The approved PA has lapsed — this is increasingly common with maintenance medications on annual review cycles


• The drug was added to the formulary's PA-required tier after the PA was first approved


• Step therapy requirements weren't documented correctly in the original submission

One thing I've seen repeatedly: pharmacies and practices assume that because a PA was approved last year, it'll carry forward automatically. It won't. PBMs refresh their formularies constantly, and 2026 has seen another round of coverage changes tied to CMS Part D restructuring under the Inflation Reduction Act. If you haven't audited your active PAs in the last six months, now is a good time.

---

Before You Appeal: Do This First

Here's where a lot of teams waste time — they jump straight into the appeal process without doing the diagnostic work. Take fifteen minutes before you draft anything.

Verify what the PBM actually has on file. Call the PBM's provider line (not the member line — you'll get better information faster) and confirm whether a PA exists, when it was approved, what drug it covers, and whether it's still active. Ask them to read back the covered NDC or drug name exactly. You'd be surprised how often the approved PA is for a 10mg tablet and the claim is submitting for a 20mg tablet.

Pull the original clinical justification. Whatever was submitted when the PA was first approved — pull that documentation now. You'll need it for the appeal, and it also tells you whether there's a gap you need to fill.

Check the prescriber information. If the prescribing provider changed, even slightly (new group affiliation, different NPI on the claim), the PA may not transfer. This is a frustrating quirk of how PBMs validate PAs at adjudication.

---

Building the Appeal: Structure Matters More Than Length

A good PA appeal isn't long — it's specific. PBM reviewers are processing dozens of appeals a day, and a five-page letter stuffed with medical jargon isn't going to help your patient any faster than a tight, well-documented two-pager.

Your appeal should include:

• The rejection details — date of service, drug, strength, quantity, reject code (75), and the plan ID/BIN/PCN


• A clear statement of why the denial was incorrect or should be overturned — don't just say "we disagree," explain why


• Clinical documentation — diagnosis codes, relevant labs, treatment history, prescriber notes supporting medical necessity


• Evidence that step therapy or formulary alternatives have been tried (or are contraindicated) — this is critical and often missing


• The prescriber's signature — some PBMs won't even log the appeal without it

One real-world example: a specialty pharmacy in Ohio was getting consistent 75 rejects on a biosimilar for a rheumatoid arthritis patient. The clinical documentation was solid, but they kept submitting appeals without noting that the patient had failed two preferred agents. Once they added a clear failure-of-alternatives summary — with dates and clinical outcomes — the appeal was approved within four business days.

The level of specificity matters. "Patient requires this medication" loses every time. "Patient initiated methotrexate on 03/14/2025, discontinued 07/22/2025 due to hepatotoxicity (ALT 3x ULN, documented in attached lab results)" wins.

---

Timelines, Escalations, and When to Push Harder

Most PBMs are required to respond to standard PA appeals within 30 days, and urgent/expedited appeals within 72 hours. Know which bucket your situation falls into — if a patient's health could deteriorate without the medication, request expedited review explicitly and document the clinical urgency in writing.

If your first-level appeal is denied, don't stop there. The appeals process typically has multiple levels:

• Internal appeal (first level) — standard initial review


• Second-level internal appeal — often goes to a physician reviewer at the PBM


• External Independent Review Organization (IRO) — required under ACA for most commercial plans, and this is where you win a surprising number of cases

IRO decisions often favor patients more than PBM internal reviews do, especially when the clinical documentation is solid. Don't assume a second denial means it's over.

Also: track everything. Create a simple log with the appeal date, submission method (fax, portal, phone), confirmation number, and expected response deadline. Missing a response deadline can trigger automatic approval with some plans — but only if you can prove you submitted in time.

---

Tools That Can Speed This Up

Let's be practical here. If you're managing multiple 75 rejects a week, doing this manually is exhausting and error-prone. A lot of practices and pharmacies are now using AI-powered appeal generators that pull in claim data and clinical notes to draft appeals automatically — saving 30-45 minutes per appeal. These tools won't replace clinical judgment, but they're genuinely useful for getting a solid first draft you can review and customize.

The key is still the clinical specificity. No tool automates that piece for you — the prescriber and clinical staff need to provide the supporting detail.

---

Wrapping Up: Don't Let Reject 75 Be a Dead End

A prior-authorization reject isn't a wall — it's a door with a specific combination. Reject 75 appeals succeed regularly when they're specific, well-documented, and submitted with the right clinical detail. The practices and pharmacies that win these consistently aren't doing anything magic. They've just built a repeatable process: verify before appealing, document failures clearly, request expedited review when it's warranted, and escalate to IRO when needed.

Your next steps:

• Audit your active PAs this week — flag any expiring in the next 90 days


• Build a PA rejection log if you don't have one


• Create a standard appeal template that includes failure-of-alternatives language


• Know your PBM-specific appeal portal URLs and deadlines before the next reject hits

Your patients are counting on someone in the system to push back when the answer is wrong. Reject 75 is worth fighting — and more often than not, it's winnable.